Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer

Gene Therapy

Volumn 20, Issue 12, 2013, Pages 1131-1139

  Freytag, S O ^a   Barton, K N ^a   Zhang, Y ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

IL 12; oncolytic adenovirus; prostate cancer; suicide gene

Indexed keywords

FLUCYTOSINE; GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 12; ONCOLYTIC ADENOVIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CELLS; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FUSION GENE; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOCOMPETENCE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; SIMIAN VIRUS 40; SUICIDE GENE; SUICIDE GENE THERAPY;

ADENOVIRIDAE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; GENE EXPRESSION; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84890114125     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.40     Document Type: Article

References (35)

1. Zelefsky M, Eastman J, Sartor O, Kantoff P. Cancer of the prostate. In: DeVita V, Lawrence T, Rosenberg (eds) Cancer: Principles & Practice of Oncology. JB Lippincott: Philadelphia, PA, USA, 2008, pp 1392-1452.
2. Freytag S, Rogulski K, Paielli D, Gilbert J, Kim JH. A novel three-pronged approach to selectively kill cancer cells: Concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther 1998; 9: 1323-1333.
3. Rogulski K, Zhang K, Kolozsvary A, Kim JH, Freytag S. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 1997; 3: 2081-2088.
4. Rogulski K, Wing M, Paielli D, Gilbert J, Kim JH, Freytag S. Double suicide gene therapy augments the therapeutic efficacy of a replication- competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Hum Gene Ther 2000; 11: 67-76.
5. Freytag S, Paielli D, Wing M, Rogulski K, Brown S, Kolozsvary A et al. Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model. Int J Radiat Oncol Biol Phys 2002; 54: 873-886.
6. Barton K, Paielli D, Zhang Y, Koul S, Brown S, Lu M et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and the ADP gene demonstrate greater efficacy without increased toxicity. Mol Ther 2006; 13: 347-356.
7. Freytag S, Barton K, Zhang Y, Paielli D, Tyson D, Nall C et al. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol Ther 2007; 15: 1600-1606.
8. Freytag S, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968-4976.
9. Freytag S, Stricker H, Pegg J, Paielli D, Pradhan D, Peabody J et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy in combination with conventional dose three-dimensional conformal radiation therapy for the treatment of newly-diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003; 63: 7497-7506.
10. Freytag S, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B et al. Five-year followup of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007; 15: 636-642.
11. Freytag S, Movsas B, Aref I, Stricker H, Peabody J, Pegg J et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy with IMRT for prostate cancer. Mol Ther 2007; 15: 1016-1023.
12. Barton K, Stricker H, Brown S, Elshaikh M, Aref I, Lu M et al. Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate. Mol Ther 2008; 16: 1761-1769.
13. Barton K, Stricker H, Elshaikh M, Pegg J, Cheng J, Zhang Y et al. Feasibility of adenovirus-mediated hNIS gene transfer and 131I radioiodine therapy as a definitive treatment for localized prostate cancer. Mol Ther 2011; 19: 1353-1359.
14. Freytag S, Stricker H, Movsas B, Kim JH. Prostate cancer gene therapy clinical trials. Mol Ther 2007; 15: 1042-1052.
15. Freytag S, Stricker H, Movsas B, Elshaikh M, Aref I, Barton K et al. Gene therapy of prostate cancer. In: Roth JA (eds) In Gene-based Therapies for Cancer. Springer: New York, NY, USA, 2010, pp 33-49.
16. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133-146.
17. Del Vecchio M, Bajetta E, Canova S, Lotze M, Wesa A, Parmiani G et al. Interleukin 12: Biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-4685.
18. Colombo M, Trinchieri G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168.
19. Tahara H, Zeh H, Storkus W, Pappo I, Watkins S, Gubler U et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-189.
20. Nasu Y, Bangma C, Hull G, Lee H-H, Hu J, Wang J et al. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Therapy 1999; 6: 338-349.
21. Paielli D, Wing M, Rogulski K, Gilbert J, Kolozsvary A, Kim JH et al. Evaluation of the biodistribution, persistence, toxicity, and potential of germ line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol Ther 2000; 1: 263-274.
22. Atkins M, Robertson M, Gordon M, Lotze M, DeCoste M, DuBois J et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3: 409-417.
23. Leonard J, Sherman M, Fisher G, Buchanan L, Larsen G, Atkins M et al. Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-g production. Blood 1997; 90: 2541-2548.
24. Fujita T, Timme T, Tabata K, Naruishi K, Kusaka N, Watanabe M et al. Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer. Gene Therapy 2007; 14: 227-236.
25. Wang H, Yang G, Timme T, Fujita T, Naruishi K, Frolov A et al. IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther 2007; 14: 819-827.
26. Egilmez N, Jong Y, Sabel M, Jacob J, Mathiowitz E, Bankert R. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: Induction of tumor regression and potent antitumor immunity. Cancer Res 2000; 60: 3832-3837.
27. Hill H, Conway T, Sabel M, Jong Y, Mathiowitz E, Bankert R et al. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: Coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res 2002; 62: 7254-7263.
28. Kilinc M, Aulakh K, Nair R, Jones S, Alard P, Kosiewicz M et al. Reversing tumor immune suppression with intratumoral IL-12: Activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8 T effectors. J Immunol 2006; 177: 6962-6973.
29. Kerkar S, Goldszmid R, Muranski P, Chinnasamy D, Yu Z, Reger R et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011; 121: 4746-4757.
30. Smyth M, Taniguchi M, Street S. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent. J Immunol 2000; 165: 2665-2670.
31. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18: 1874-1884.
32. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila P, Ugolini M et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297-4309.
33. Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013; 19: 2734-2744.
34. Heo J, Reid T, Ruo L, Breitbach C, Rose S, Bloomston M et al. Randomized dosefinding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19: 329-336.
35. Kaufman H, Kim D, DeRaffele G, Mitcham J, Coffin R, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010; 17: 718-730.